We are assessing the safety and tolerability of EryDex in individuals with Ataxia Telangiectasia. Additionally, we’re exploring its potential effects on neurological symptoms.
Health conditions and diseases that the clinical trial is designed to study and treat.
Ataxia Telangiectasia (A-T) is a rare genetic disorder that affects coordination and immune function, leading to symptoms such as difficulty with movement, increased susceptibility to infections, and a higher risk of certain cancers.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
